A detailed history of Qube Research & Technologies LTD transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 877,043 shares of MRSN stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
877,043
Previous 992,565 11.64%
Holding current value
$1.42 Million
Previous $2 Million 16.94%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.23 - $2.25 $142,092 - $259,924
-115,522 Reduced 11.64%
877,043 $1.66 Million
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $65,740 - $146,271
32,870 Added 3.43%
992,565 $2 Million
Q1 2024

May 14, 2024

BUY
$2.16 - $5.94 $2.07 Million - $5.7 Million
959,695 New
959,695 $4.3 Million
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $146,885 - $455,439
-47,690 Reduced 18.94%
204,106 $671,000
Q1 2023

May 15, 2023

BUY
$4.0 - $7.02 $661,640 - $1.16 Million
165,410 Added 191.48%
251,796 $1.03 Million
Q4 2022

Feb 14, 2023

BUY
$5.65 - $7.86 $176,828 - $245,994
31,297 Added 56.81%
86,386 $506,000
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $147,988 - $255,704
31,963 Added 138.21%
55,089 $372,000
Q2 2022

Aug 15, 2022

SELL
$2.84 - $5.0 $784,771 - $1.38 Million
-276,328 Reduced 92.28%
23,126 $107,000
Q1 2022

May 09, 2022

BUY
$3.74 - $6.63 $903,946 - $1.6 Million
241,697 Added 418.47%
299,454 $1.2 Million
Q4 2021

Feb 01, 2022

BUY
$5.48 - $9.86 $316,508 - $569,484
57,757 New
57,757 $359,000
Q3 2021

Nov 12, 2021

SELL
$8.56 - $14.47 $536,583 - $907,051
-62,685 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$13.28 - $18.07 $832,456 - $1.13 Million
62,685 New
62,685 $851,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $157M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.